VALN Valneva Vaccines: Earnings per share for the trailing year

Official company branding of Valneva Corp (VALN)

Strict temperature logistics for pharmaceuticals dictate high delivery costs, as confirmed by the annual EPS (TTM) growth statistics on the GURU.Markets chart, where the value -134.80 describes the current level. Valneva SE (VALN) fundamentals rely on the unique IXCHIQ vaccine and a partnership with Pfizer. Furthermore, the business is based on stable demand, which renders the asset a defensive asset during recessionary periods.

VALN Valneva Earnings per share for the last twelve months (02/11/2024 - 11/14/2026)

Valneva Pharma - analytical breakdowns and key metrics (VALN)

- market price and analyst price targets:
Market Chart valneva.com|VALN - Price Target Chart
- company stock capitalization data:
Market Value Valneva Corp|VALN - Real Price to Acquire Entire Company
- issuer book value statistics:
Book Value per Share Valneva|VALN - Company Book Value|Market Capitalization to Book Value valneva.com|VALN - Cumulative Company Assets
- debt burden and liquidity indicators:
Debt to Equity Valneva SE|VALN - Long-Term Debt to Capital|Short-Term Debt to Capital Valneva Vaccines|VALN - Company Debts|Debt to Book Capitalization Ratio Valneva Corp|VALN - Company Long-Term Debt|Company Short-Term Indebtedness Valneva|Immediate Liquidity valneva.com
- earnings and multiples data:
VALN - Net Income|Expected Profit Valneva SE|VALN - P/E Multiple|Forward P/E Multiple Valneva Corp|VALN - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Valneva Corp|VALN - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Valneva|VALN - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months valneva.com|VALN - Net earnings per share growth this year|Net earnings per share growth forecast for next year Valneva SE
- revenue and sales details:
VALN - Revenue and Sales Volume|Projected Sales Volume valneva.com|VALN - Price-to-Revenue Ratio|Price-to-Projected Revenue Ratio Valneva Corp
Initial company analysis:valneva.com - VALN
Flagship merchandise of Valneva Pharma

For Valneva SE (VALN), the earnings per share trend reflects the operational efficiency of its own sterile manufacturing capacities in Europe and the stability of vaccine supplies. By analyzing the 12-month YoY EPS history, an investor assesses the rolling annual net income growth rate, which helps identify market imbalances and avoid purchasing the asset at a local valuation peak.

Competitor analysis

Net earnings per share for the last four quarters gilead.com GILD|Cidara Therapeutics Corp (CDTX) - Earnings per share for the last twelve months|Novavax Inc - Earnings per share for the trailing year|Net earnings per share for the last 12 months CVAC|Net earnings per share (EPS TTM) Vir Corp|Earnings per share for the last twelve months SIGA Technologies, Inc. (SIGA)|Net earnings per share for the last four quarters emergentbiosolutions.com|Atea Pharmaceuticals, Inc. - Net earnings per share for the last 12 months|Invivyd Inc - Earnings per share for the last twelve months|Enanta - Net earnings per share (EPS TTM)|INO - Net earnings per share (EPS TTM)|HilleVax, Inc. (HLVX) - Earnings per share for the last twelve months|KLRS (kalaristx.com) - Earnings per share for the last twelve months|Earnings per share for the last twelve months Dyadic International Inc|Earnings per share for the last 12 months NNVC (NanoViricides Corp)|Net earnings per share (EPS TTM) TLPH|COCP - Net earnings per one share for the last twelve months|Traws Pharma - Net earnings per share for the last 12 months|Dogwood Therapeutics Inc. - Earnings per share for the last twelve months|Qualigen Therapeutics, Inc. - Net earnings per share (EPS TTM)|ALVR - Net earnings per share (EPS TTM)|VBIV (vbivaccines.com) - Net earnings per share for the last 12 months|Virios Therapeutics, Inc. - Earnings per share for the trailing year|Earnings per share for the last twelve months Vaxart Inc.